• Ruanyun Edai Technology signed an agreement granting BioNexus Gene Lab an exclusive Cogni AI license for Malaysian healthcare.
• The 10-year license is renewable for up to 20 years, with a 10% royalty on qualifying technology receipts and no guaranteed revenue.
• Contractual license consideration is US$3.5 million, payable through 410,000 BioNexus common shares valued at US$520,700 at October 2, 2026, closing prices.
• A separate exchange involves 150,000 BioNexus common shares for 500,000 Ruanyun ordinary shares, with no cash payment.
• Closing remains subject to testing acceptance and approvals; either non-defaulting party may terminate if closing misses March 31, 2027, unless extended.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ruanyun Edai Technology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-001381), on October 30, 2026, and is solely responsible for the information contained therein.